Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Cerebrolysin (60mg Vial) Dosage Chart - Peptide Dosages

Cerebrolysin (60mg Vial) Dosage Protocol Porcine-brain-derived neuropeptide mixture — approved abroad for stroke/dementia/TBI, not FDA-approved in the US. Mix & measure Cerebrolysin · 60 mg Pre-filled with this protocol’s recommended BAC water and documented s

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Cerebrolysin (60mg Vial) Dosage Protocol

Porcine-brain-derived neuropeptide mixture — approved abroad for stroke/dementia/TBI, not FDA-approved in the US.

Mix & measure Cerebrolysin · 60 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Dosing & Reconstitution Guide

A single practical dilution with accurate once-daily dosing, step by step

Standard / Gradual Approach (3 mL = 20 mg/mL)

Reconstitute: Add 3.0 mL bacteriostatic water to one 60 mg vial → final concentration 20 mg/mL. (Applies to a research-grade lyophilized powder only.)

Typical daily range: 20 mg/day (Week 1), titrated to 24, 28 then 32 mg/day; from Week 2 onward the daily amount is split into AM and PM injections.

Easy measuring: At 20 mg/mL, 1 unit = 0.01 mL = 0.2 mg on a U-100 syringe, so units = mg ÷ 0.2 (e.g. 20 mg = 100 units, 32 mg = 160 units).

Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01Pemvidutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Pemvidutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
02Amycretin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Amycretin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
03Ecnoglutide — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Ecnoglutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
04GHK (Copper-Free) — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 50 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 50 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. GHK (Copper-Free) is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
05Cortexin — frequently asked questions

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units. There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units. On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand. Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product. Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose. No. Cortexin is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Source: dosagepeptide.com ↗
Research context

Read sources and limitations before applying a claim.

Where the Human Evidence Stands — and Why It Does Not Reach Lipogenesis

AOD-9604’s clinical record lives almost entirely in obesity, and understanding it is the fairest way to gauge whether any of the preclinical antilipogenic promise translated to people. The short version: it was tested seriously, in humans, at scale, and it did not deliver on its primary endpoint — and none of the human work measured lipogenesis at all. Across development, AOD-9604 was studied in roughly six human clinical trials enrolling more than 900 participants in total, a tally that derives from the sponsor’s development-program summary rather than a single publication.10 The centerpiece early study, a 12-week Phase 2 evaluation in obese adults (METAOD005) using once-daily oral dosing across several dose arms, was encouraging: the 1 mg arm reportedly lost more weight than placebo, and the results generated optimistic press.10 But the pivotal, longer, more rigorously controlled 24-week study (METAOD006) — a randomized, double-blind, placebo-controlled, multicenter trial that is the single published RCT on the compound — found that the weight-loss difference between AOD-9604 and placebo did not reach statistical significance at the primary endpoint, especially against a background of intensive diet and exercise.10 Development as an obesity drug was terminated in 2007. Two points matter for the antilipogenic question. First, every human study used weight and body-composition endpoints, plus safety and pharmacokinetic measures. None used the tools that actually quantify de novo lipogenesis in people — stable-isotope tracers (for example, deuterated water incorporation into palmitate), adipose or hepatic lipogenic-gene expression, or measured lipogenic flux. So even the human trials that exist are silent on whether AOD-9604 reduces fat synthesis; they measured the downstream outcome (weight), not the mechanism (lipogenesis), and the downstream outcome was not robustly positive. Second, the reassuring endocrine profile held up: the compound was reported not to raise IGF-1 and not to impair glucose tolerance, consistent with the “GH activity modulation” design.1 Trials ~6 studies, >900 participants total10 Pivotal design 24-week randomized, double-blind, placebo-controlled, multicenter (METAOD006); oral10 Primary endpoint Weight difference vs placebo did NOT reach statistical significance10 Lipogenesis measured? No — no DNL tracer, lipogenic-gene, or flux endpoints in any human study Endocrine profile No reported IGF-1 rise; no impaired glucose tolerance1 Outcome Obesity development halted in 200710 The honest reading is stark: the compound’s best-evidenced outcome (fat loss in obesity) was itself not robustly demonstrated in humans, and its proposed mechanism (reduced lipogenesis) was never measured in humans at all. Extrapolating from “inhibited ACC in rat fat pads” to “reduces lipogenesis in people” is a leap across species, tissues, and measurement methods, with no human data on the far side. For a measured look at how the clinical results are often characterized, see the site’s summary of what clinical trials indicate about the fat-burning potential of AOD-9604.

Source: dosagepeptide.com ↗

Handling and Reconstitution in a Research Context

This section describes how NAD+ and its precursors are handled as laboratory materials, because handling directly affects the reproducibility and interpretability of research. It is not a how-to for self-administration and carries no implication that these compounds should be used to address Parkinson’s disease or any other condition outside a properly authorized study. The clinical trials discussed above used pharmaceutical-grade oral capsules manufactured and quality-controlled to trial standards, which is a very different thing from a lyophilized research vial. Oral precursors such as NR and NMN are the simplest to handle because they are supplied as capsules or powders intended for oral use, and the human Parkinson’s trials all used the oral route.1,2 Their main practical vulnerabilities are moisture and heat: NMN in particular is hygroscopic and can degrade if exposed to humidity, so powders are kept sealed, cool, and dry, and analytical labs verify content by high-performance liquid chromatography rather than trusting label claims. For any quantitative experiment, confirming compound identity and purity before use is a basic control, because degraded or mislabeled material is a common hidden source of irreproducibility. Lyophilized (freeze-dried) NAD+ intended for reconstitution introduces additional handling considerations that mirror those of injectable research peptides. Freeze-dried material is generally stored frozen, often at minus 20 degrees Celsius or colder, with colder storage preferred for long-term stability, and is protected from light and repeated freeze-thaw cycling, each of which can degrade sensitive dinucleotides. Reconstitution is typically performed with a sterile diluent added slowly down the inner wall of the vial rather than directly onto the powder, followed by gentle swirling rather than vigorous shaking, since mechanical agitation and foaming can damage the molecule; the vial is then allowed to dissolve fully before use. Once in solution, NAD+ is far less stable than in its dried state and is kept refrigerated at roughly 2 to 8 degrees Celsius and used within a limited window, on the order of days to a couple of weeks depending on conditions, because aqueous NAD+ hydrolyzes over time. Concentration is a function of the diluent volume added to a known mass; laboratories track this explicitly so that any downstream measurement is traceable to a defined concentration. General principles of this kind are covered in the site’s peptide reconstitution guide and the associated reconstitution calculator, which exist to support accurate laboratory record-keeping rather than to encourage use. Two broader points frame all of this. First, handling quality is a research-validity issue before it is anything else: an experiment run with degraded, contaminated, or inaccurately concentrated material produces uninterpretable data, which is one way that poorly controlled work generates the exaggerated claims this article is trying to counter. Second, none of these handling details change the compounds’ status. A carefully reconstituted NAD+ solution is still an unapproved research material, and meticulous technique does not convert a preclinical hypothesis into a validated Parkinson’s treatment. The site’s general research compound reference index catalogs handling parameters for many such materials on the same understanding: they are educational references for people working in controlled settings, not endorsements of use.

Source: dosagepeptide.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

How-to reference

How to convert mcg to mg (and back)

Because the factor is exactly 1000, every conversion is a decimal-point move of three places — no calculator strictly required once you see the pattern: mcg → mg: divide by 1000, i.e. move the decimal point three places to the left. 500 mcg → 0.5 mg; 100 mcg → 0.1 mg; 1500 mcg → 1.5 mg. mg → mcg: multiply by 1000, i.e. move the decimal point three places to the right. 0.5 mg → 500 mcg; 2 mg → 2000 mcg; 1.25 mg → 1250 mcg. The tool above does the same move for you and trims trailing zeros, so you can paste in any value — whole or fractional — and read the exact counterpart.

Source: dosagepeptide.com ↗
Dosage reference

Oxytocin (5mg Vial) Dosage Protocol

Nonapeptide hormone (oxytocin-receptor agonist) — FDA-approved for obstetric use; social/wellness uses are research-only.

Source: dosagepeptide.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →